Literature DB >> 7615113

Follicle-stimulating hormone versus human menopausal gonadotropin for in vitro fertilization cycles: a meta-analysis.

S Daya1, J Gunby, E G Hughes, J A Collins, M A Sagle.   

Abstract

OBJECTIVE: To conduct a systematic overview of available data comparing FSH with hMG in IVF treatment cycles.
DESIGN: A meta-analysis of randomized trials of FSH versus hMG use in ovarian stimulation protocols, with or without GnRH agonists, in IVF treatment cycles. Search strategies included on-line searching of the National Library of Medicine MEDLINE data base from 1975 to 1993 and hand searching of bibliographies of relevant publications and reviews and abstracts of scientific meetings. Common odds ratio (OR) and overall absolute treatment effect were calculated after demonstrating homogeneity of treatment effect across all trials. MAIN OUTCOME MEASURES: Clinical pregnancy rates per cycle start, per cycle reaching oocyte retrieval, and per cycle reaching ET.
RESULTS: Eight trials met the inclusion criteria. The overall OR in favor of FSH for cycle start, oocyte retrieval, and ET were 1.71, 1.69 and 1.70, respectively, and represented an overall absolute treatment effect of 8.5%, 8.0% and 8.3%, respectively.
CONCLUSIONS: This meta-analysis demonstrates that in IVF cycles the use of FSH is associated with a significantly higher clinical pregnancy rate than hMG.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7615113

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  7 in total

Review 1.  The role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment.

Authors:  Mohamed F M Mitwally; Robert F Casper; Michael P Diamond
Journal:  Reprod Biol Endocrinol       Date:  2005-10-04       Impact factor: 5.211

2.  Influence of pituitary suppression with triphasic or monophasic oral contraceptives on the outcome of in vitro fertilization and embryo transfer.

Authors:  Ming-Ting Chung; Yung-Chieh Tsai; Sheng-Hsien Chen; Tao-Chuan Loo; Hsun-Han Tang; Liang-Yin Lin
Journal:  J Assist Reprod Genet       Date:  2006-08-16       Impact factor: 3.412

3.  Exogenous luteinizing hormone (LH) increases estradiol response patterns in poor responders with low serum LH concentrations.

Authors:  J Y Phelps; L Figueira-Armada; A S Levine; N P Vlahos; D Roshanfekr; H A Zacur; J E Garcia
Journal:  J Assist Reprod Genet       Date:  1999-08       Impact factor: 3.412

4.  A randomized prospective cross-over study of highly purified follicle-stimulating hormone and human menopausal gonadotrophin for ovarian hyperstimulation in women aged 37-41 years.

Authors:  S Bassil; C Wyns; J Donnez
Journal:  J Assist Reprod Genet       Date:  2000-02       Impact factor: 3.412

Review 5.  Contemporary pharmacological manipulation in assisted reproduction.

Authors:  Judith A F Huirne; Cornelis B Lambalk; Andre C D van Loenen; Roel Schats; Peter G A Hompes; Bart C J M Fauser; Nick S Macklon
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Lutropin alpha, recombinant human luteinizing hormone, for the stimulation of follicular development in profoundly LH-deficient hypogonadotropic hypogonadal women: a review.

Authors:  Bernd Th Krause; Ralf Ohlinger; Annette Haase
Journal:  Biologics       Date:  2009-07-13

Review 7.  Overriding follicle selection in controlled ovarian stimulation protocols: quality vs quantity.

Authors:  Richard L Stouffer; Mary B Zelinski-Wooten
Journal:  Reprod Biol Endocrinol       Date:  2004-06-16       Impact factor: 5.211

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.